US20050234432A1 - Therapeutic treatment of disorders based on timing information - Google Patents
Therapeutic treatment of disorders based on timing information Download PDFInfo
- Publication number
- US20050234432A1 US20050234432A1 US11/093,747 US9374705A US2005234432A1 US 20050234432 A1 US20050234432 A1 US 20050234432A1 US 9374705 A US9374705 A US 9374705A US 2005234432 A1 US2005234432 A1 US 2005234432A1
- Authority
- US
- United States
- Prior art keywords
- drug
- patient
- pump
- time
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3523—Communication with implanted devices, e.g. external control using telemetric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1003—Spinal column
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
Definitions
- the present invention relates to neurostimulation or drug infusion devices, and more particularly relates to techniques for activating or deactivating a neurostimulator or drug delivery system based on time-of-day or biological rhythmic patterns.
- Neurostimulation devices and drug delivery devices are now capable of treating any number of disorders as well as symptoms of disorders.
- an electrical lead having one or more electrodes is typically implanted near a specific site in the brain or spinal cord of a patient.
- the lead is coupled to a signal generator which delivers electrical energy through the electrodes to nearby neurons and neural tissue.
- the electrical energy delivered through the electrodes creates an electrical field causing excitation of the nearby neurons to directly or indirectly treat the neurological disorder or a symptom of the disorder.
- a catheter coupled to a pump is implanted near a treatment site in the brain or spinal cord. These systems are commonly implanted within the body and are operated by a power source such as a battery.
- the present invention overcomes the above-noted and other shortcomings of the prior art neurostimulation devices.
- the present invention provides a technique for shutting off the electrical stimulation or drug delivery during periods when the treatment therapy is not desired.
- the neurostimulator has a timer or a clock capable of turning on or off the treatment therapy at predetermined times. Accordingly, the system may be automatically turned off at a time when the patient is usually fast asleep and turned on at a time prior to the patient awakening.
- the present invention includes an implantable signal generator, a timer coupled to the signal generator for providing timing information to the signal generator, and circuitry (a microprocessor) within the signal generator for determining whether the signal generator is turned off or on in response to the timer information.
- Timer may alternatively be a real time clock.
- the present invention includes a sensor coupled to the signal generator for generating a signal indicative of whether a patient is asleep or awake.
- the microprocessor receives time of day information from the timer and information as to whether the patient is awake or asleep from the sensor. Based on these signals, the microprocessor may automatically initiate or stop the treatment therapy to the patient.
- the present invention may also be implemented within an implantable drug delivery system in accordance with the principles of the above-described embodiments.
- FIG. 1 depicts a neurostimulation device in accordance with an embodiment of the present invention
- FIG. 2 is a schematic block diagram of the circuitry of device or signal generator in accordance with a preferred embodiment of the present invention
- FIG. 2A is a schematic block diagram of the circuitry of device or signal generator in accordance with another preferred embodiment of the present invention.
- FIG. 3 illustrates a schematic block diagram of another embodiment of signal generator wherein timer is coupled to a power source such as battery of signal generator;
- FIG. 4 discloses another embodiment of the present invention wherein a sensor provides feedback as to whether the patient is awake or asleep to determine whether signal generator should be turned on or off;
- FIG. 5 illustrates a schematic block diagram of the signal generator of FIG. 2 including a sensor signal input from sensor
- FIG. 6 depicts a drug infusion system in accordance with an embodiment of the present invention.
- FIG. 1 depicts a neurostimulation device 10 in accordance with an embodiment of the present invention.
- Device 10 made in accordance with the preferred embodiment is preferably implanted below the skin of a patient or, alternatively, may be an external device.
- Device 10 may be implanted as shown in FIG. 1 , in the abdomen or any other portion of the body.
- a lead 22 A is positioned to stimulate a specific site in a brain (B).
- Device 10 may take the form of a modified signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II.
- Lead 22 A may take the form of any of the leads sold with the Model 7424, for stimulating the brain, and is coupled to device 10 by a conventional conductor 22 .
- lead 22 A may be any lead suitable for stimulation of a spinal cord.
- Lead 22 A may include a paddle lead, a lead having recording and stimulation electrodes, or a combination catheter/lead capable of providing electrical stimulation and drug delivery.
- the distal end of lead 22 A terminates in one or more stimulation electrodes generally implanted into a portion of the brain by conventional stereotactic surgical techniques. Any number of electrodes may be used for various applications.
- Each of the electrodes is individually connected to device 10 through lead 22 A and conductor 22 .
- Lead 22 A is surgically implanted through a hole in the skull and conductor 22 is implanted between the skull and the scalp.
- Conductor 22 is joined to implanted device 10 in the manner shown.
- Conductor 22 may be divided into twin leads 22 A and 22 B that are implanted into the brain bilaterally as shown.
- lead 22 B may be supplied with stimulating pulses from a separate conductor and signal generator.
- Leads 22 A and 22 B could be two electrodes in 1) two separate nuclei that potentiate each other's effects or 2) nuclei with opposite effects with the stimulation being used to fine tune the response through the application of one stimulation pattern to one cite and the application of another stimulation pattern to the other cite.
- FIG. 2 is a schematic block diagram of the circuitry of device or signal generator 10 in accordance with a preferred embodiment of the present invention.
- signal generator 10 includes a timer 201 coupled to a microprocessor or a controller 200 .
- Timer 201 establishes when the system is “on” or “off.” in accordance with predetermined counts of timer 201 .
- the operator or patient may calibrate timer 201 such that signal generator 10 is “on” at a specific time in the morning right before the patient usually wakes up and is “off” at a specific time in the evening after the patient has fallen asleep. This calibration may be accomplished during the implantation of signal generator 10 .
- timer 201 may be remotely calibrated to adjust for changing time conditions or preferences of the patient (such as changing sleep habits). The additional components of signal generator 10 are discussed in further detail herein.
- FIG. 3 illustrates a schematic block diagram of another embodiment of signal generator 10 wherein timer 201 is coupled to a power source 203 such as battery of signal generator 10 .
- timer 201 disconnects power source 203 from providing any electrical energy to signal generator 10 .
- timer 201 reconnects power source 203 to provide electrical energy to signal generator 10 . Operation of signal generator 10 during the “on” stage may be handled under techniques known in the art.
- timer 201 may be a real time clock.
- Clock may be adjusted manually such as, for example, by a switch 230 ( FIG. 2A ) that the patient may access via telemetry or, alternatively, clock may be responsive to an external source, such as a wristwatch or a central satellite, to ensure that the clock is timed properly.
- clock may be periodically adjusted to reflect the accurate time-of-day. As such, changes due to daylight savings time changes as well as changes in time zones (if the patient is traveling outside of his/her time zone) may be automatically accounted.
- FIG. 4 discloses another embodiment of the present invention wherein a sensor 130 provides feedback as to whether the patient is awake or asleep to determine whether signal generator 10 should be turned on or off.
- sensor 130 may sense a condition of a patient indicating whether the patient is asleep such as whether the eyes are closed, the breathing patterns, or the heart rate.
- device 10 shuts on or off in response to any number of physical, biological and/or chemical rhythms of the body indicative of whether the patient is sleeping.
- the system may sense whether the patient's eyes shut for an extended period of time signifying that the patient is napping, sleeping or resting.
- the system may monitor activity or motion, heart rate, or respiration.
- sensor 130 may be used to sense the above characteristics of the body. More detailed description of sensor 130 and other examples of sensors are disclosed in U.S. Pat. No. 5,716,377 entitled “Method of Treating Movement Disorders By Brain Infusion,” issued on Feb. 10, 1998 and assigned to Medtronic, Inc., which is incorporated herein by reference in its entirety. Other such sensors are also disclosed in U.S. Pat. Nos. 5,683,422; 5,702,429; 5,713,923; 5,716,316; 5,792,186; 5,814,014; and 5,824,021, all of which are incorporated herein by reference in their entireties.
- Signal generator 10 may be automatically turned on or off if any of the conditions sensed by sensor 130 indicates that the patient is sleeping. Sensor 130 may be used in conjunction with or as an alternative to timer 201 (or a real time clock). If used in conjunction with timer 201 , signal generator 10 may operate with a default of being “off” at night and a default of being “on” during the day. The default is determined by timer 201 . During the day, device 10 may shut off only when a certain threshold of characteristics are sensed by sensor 130 such that it is clear that the patient is asleep. At night when the patient is normally asleep, device 10 may be turned on only when sensor 130 senses characteristics that clearly indicate that the patient has awaken. Sensor 130 provides information to signal generator 10 to determine whether to deviate from the default. These threshold parameters may be adjusted by the physician or the patient. The patient may also have the capability to manually turn on or off signal generator 10 as provided in the art.
- Sensor 130 may also be used to provide closed-loop feedback control of the treatment therapy during periods when device 10 is in operation.
- one or more additional sensors may be implemented for feedback control.
- the additional sensor is attached to or implanted into a portion of a patient's body suitable for detecting symptoms of a disorder being treated, such as a movement disorder or ischemic pain.
- the additional sensor is adapted to sense an attribute of the symptom to be controlled or an important related symptom.
- sensor may be a motion detector implanted in arm 122 as shown in FIG. 4 .
- Such feedback control techniques are disclosed in the patents described above.
- the output of sensor 130 is coupled by cable 132 to signal generator 10 .
- the output of an external sensor would communicate with signal generator 10 via telemetry.
- sensor 130 monitors heart rate and optionally movement.
- FIG. 5 illustrates a schematic block diagram of the signal generator 10 of FIG. 2 including a sensor signal input from sensor 130 .
- Sensor 130 is coupled to an analog to digital converter 206 of signal generator 10 .
- the output of the analog to digital converter 206 is connected to a microprocessor 200 through a peripheral bus 202 including address, data and control lines. Depending upon the particular sensor signal used, an analog to digital converter would not be necessary.
- the output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for signal generator 10 .
- Microprocessor 200 is coupled to timer 201 to receive timing information and to sensor 130 to receive patient information. Microprocessor 200 may then responsively determine whether the treatment therapy should be turned on or off. Other componentry of signal generator 10 is shown to generate the desired signal pulsing parameters and/or to provide feedback control of the treatment therapy. The present invention may be practiced without microprocessor 200 . For example, a controller or electrical circuitry having the desired functionality may be implemented in place of microprocessor 200 to receive the timer and/or sensor information and process the information to determine whether treatment therapy is to be delivered.
- the drug infusion system includes a pump 410 having at least one reservoir for storing at least one drug.
- the drug may be delivered via a catheter 422 .
- Catheter 422 may be coupled to a single tube 422 A or tube 422 A may be divided into twin tubes, tube 422 A and a second tube (not shown), that are implanted into the brain bilaterally.
- the second tube may supply drugs from a second catheter and pump or may supply drugs from catheter 422 to a second location within the brain B.
- Such drug infusion systems that may incorporate the present invention are disclosed in U.S. Pat. Nos.
- the drug pump may include similar componentry as that of the signal generators 10 discussed in FIGS. 2, 3 and 5 .
- the present invention may be utilized in a number of different treatment therapies, including, but not limited to, treatment of pain, movement disorders and other neurological disorders such as epilepsy, to provide a mechanism to automatically turn off treatment therapy during periods that it is not required or necessary.
- the term disorder includes any disorder, illness or maladies.
- the present invention may automatically turn on the treatment therapy during or right before the patient requires the treatment therapy.
Abstract
Techniques for operation of neurostimulation or drug delivery devices to adjust treatment therapy during specific times of the day are disclosed. Advantageously, battery usage and/or drug dosage can be reduced during periods when treatment therapy need not be provided. Furthermore, tolerance of the patient toward the neurostimulation or drug delivery that may develop from the regular application of electrical stimulation or treatment therapy may be reduced or slowed. In one embodiment, a device includes a real time clock for shutting off the device in accordance with a preset schedule. The device can be configured to turn off after the patient has fallen asleep and turns on right before the patient awakes. The device may include a sensor for sensing symptoms related to a disorder being treated and treatment therapy can be adjusted accordingly.
Description
- The application is a continuation of application Ser. No. 10/000,638, filed on Oct. 31, 2001, which was a divisional of and claimed priority to application Ser. No. 09/303,144, filed Apr. 30, 1999, this application therefore claims priority to both prior applications and both are incorporated in their entirety herein.
- The present invention relates to neurostimulation or drug infusion devices, and more particularly relates to techniques for activating or deactivating a neurostimulator or drug delivery system based on time-of-day or biological rhythmic patterns.
- Neurostimulation devices and drug delivery devices are now capable of treating any number of disorders as well as symptoms of disorders. In the context of neurostimulators, an electrical lead having one or more electrodes is typically implanted near a specific site in the brain or spinal cord of a patient. The lead is coupled to a signal generator which delivers electrical energy through the electrodes to nearby neurons and neural tissue. The electrical energy delivered through the electrodes creates an electrical field causing excitation of the nearby neurons to directly or indirectly treat the neurological disorder or a symptom of the disorder. In the context of a drug delivery system, a catheter coupled to a pump is implanted near a treatment site in the brain or spinal cord. These systems are commonly implanted within the body and are operated by a power source such as a battery.
- Recent advances have allowed these neurostimulation devices and drug delivery systems to adjust treatment in accordance with the patient's needs. Generally, these systems incorporate a sensor for sensing a physical or chemical characteristic of the body and generating a sensor signal in response. The sensor signal may then be used to adjust the treatment therapy. U.S. Pat. No. 5,716,377, for example, discloses a method of treating movement disorders by closed loop brain stimulation.
- These systems, however, provide electrical stimulation or drug delivery regardless of the time of day or the patient's needs. These systems are capable of adjusting the treatment but are incapable of recognizing periods when a patient does not require any therapy. For example, patients often will not require any stimulation or drug therapy during periods when he/she is resting or sleeping. During such time periods, the manifestation of the movement disorder may be minimal or even non-existent. This is often the case for patients suffering from movement disorders and certain types of pain.
- Stimulation or drug delivery at times when it is not required by the patient unnecessarily depletes the battery or the drug reserve which is often implanted within the body. This requires more frequent surgical procedures to replace the spent battery or more frequent drug injections. An even greater concern with continuous therapy systems is that the patient may develop a higher tolerance to the treatment, thereby requiring higher dosage or stronger stimulation to achieve the desired result.
- Often, physicians will request the patient to turn off his/her neurostimulator at night. This requires the patient or care giver to manually turn the device off at night before falling asleep and turn on the device after waking up the next day. However, after the neurostimulator is turned off but before the patient has fallen asleep, symptoms of movement disorders, illnesses or other maladies (such as tremor) or pain often return, thereby rendering sleep difficult. Accordingly, there remains a need in the art for automatically shutting off the electrical stimulation or drug delivery during periods when the patient does not require treatment therapy.
- As explained in more detail below, the present invention overcomes the above-noted and other shortcomings of the prior art neurostimulation devices. The present invention provides a technique for shutting off the electrical stimulation or drug delivery during periods when the treatment therapy is not desired. In one embodiment, the neurostimulator has a timer or a clock capable of turning on or off the treatment therapy at predetermined times. Accordingly, the system may be automatically turned off at a time when the patient is usually fast asleep and turned on at a time prior to the patient awakening. In the context of a neurostimulation device, the present invention includes an implantable signal generator, a timer coupled to the signal generator for providing timing information to the signal generator, and circuitry (a microprocessor) within the signal generator for determining whether the signal generator is turned off or on in response to the timer information. Timer may alternatively be a real time clock.
- In another embodiment, the present invention includes a sensor coupled to the signal generator for generating a signal indicative of whether a patient is asleep or awake. The microprocessor receives time of day information from the timer and information as to whether the patient is awake or asleep from the sensor. Based on these signals, the microprocessor may automatically initiate or stop the treatment therapy to the patient.
- The present invention may also be implemented within an implantable drug delivery system in accordance with the principles of the above-described embodiments.
- These and other advantages and features of the invention will become apparent upon reading the following detailed description and referring to the accompanying drawings in which like numbers refer to like parts throughout and in which:
-
FIG. 1 depicts a neurostimulation device in accordance with an embodiment of the present invention; -
FIG. 2 is a schematic block diagram of the circuitry of device or signal generator in accordance with a preferred embodiment of the present invention; -
FIG. 2A is a schematic block diagram of the circuitry of device or signal generator in accordance with another preferred embodiment of the present invention. -
FIG. 3 illustrates a schematic block diagram of another embodiment of signal generator wherein timer is coupled to a power source such as battery of signal generator; -
FIG. 4 discloses another embodiment of the present invention wherein a sensor provides feedback as to whether the patient is awake or asleep to determine whether signal generator should be turned on or off; -
FIG. 5 illustrates a schematic block diagram of the signal generator ofFIG. 2 including a sensor signal input from sensor; and -
FIG. 6 depicts a drug infusion system in accordance with an embodiment of the present invention. -
FIG. 1 depicts aneurostimulation device 10 in accordance with an embodiment of the present invention.Device 10 made in accordance with the preferred embodiment is preferably implanted below the skin of a patient or, alternatively, may be an external device.Device 10 may be implanted as shown inFIG. 1 , in the abdomen or any other portion of the body. Alead 22A is positioned to stimulate a specific site in a brain (B).Device 10 may take the form of a modified signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II.Lead 22A may take the form of any of the leads sold with the Model 7424, for stimulating the brain, and is coupled todevice 10 by aconventional conductor 22. Alternatively,lead 22A may be any lead suitable for stimulation of a spinal cord.Lead 22A may include a paddle lead, a lead having recording and stimulation electrodes, or a combination catheter/lead capable of providing electrical stimulation and drug delivery. - As shown in
FIG. 1 , the distal end oflead 22A terminates in one or more stimulation electrodes generally implanted into a portion of the brain by conventional stereotactic surgical techniques. Any number of electrodes may be used for various applications. Each of the electrodes is individually connected todevice 10 throughlead 22A andconductor 22.Lead 22A is surgically implanted through a hole in the skull andconductor 22 is implanted between the skull and the scalp.Conductor 22 is joined to implanteddevice 10 in the manner shown. -
Conductor 22 may be divided into twin leads 22A and 22B that are implanted into the brain bilaterally as shown. Alternatively, lead 22B may be supplied with stimulating pulses from a separate conductor and signal generator.Leads -
FIG. 2 is a schematic block diagram of the circuitry of device orsignal generator 10 in accordance with a preferred embodiment of the present invention. As preferred,signal generator 10 includes atimer 201 coupled to a microprocessor or acontroller 200.Timer 201 establishes when the system is “on” or “off.” in accordance with predetermined counts oftimer 201. The operator or patient may calibratetimer 201 such thatsignal generator 10 is “on” at a specific time in the morning right before the patient usually wakes up and is “off” at a specific time in the evening after the patient has fallen asleep. This calibration may be accomplished during the implantation ofsignal generator 10. As preferred,timer 201 may be remotely calibrated to adjust for changing time conditions or preferences of the patient (such as changing sleep habits). The additional components ofsignal generator 10 are discussed in further detail herein. -
FIG. 3 illustrates a schematic block diagram of another embodiment ofsignal generator 10 whereintimer 201 is coupled to apower source 203 such as battery ofsignal generator 10. During “off” periods,timer 201 disconnectspower source 203 from providing any electrical energy to signalgenerator 10. During the “on” stage,timer 201 reconnectspower source 203 to provide electrical energy to signalgenerator 10. Operation ofsignal generator 10 during the “on” stage may be handled under techniques known in the art. - In yet another embodiment of the present invention,
timer 201 may be a real time clock. Clock may be adjusted manually such as, for example, by a switch 230 (FIG. 2A ) that the patient may access via telemetry or, alternatively, clock may be responsive to an external source, such as a wristwatch or a central satellite, to ensure that the clock is timed properly. Advantageously under the latter embodiment, clock may be periodically adjusted to reflect the accurate time-of-day. As such, changes due to daylight savings time changes as well as changes in time zones (if the patient is traveling outside of his/her time zone) may be automatically accounted. -
FIG. 4 discloses another embodiment of the present invention wherein asensor 130 provides feedback as to whether the patient is awake or asleep to determine whethersignal generator 10 should be turned on or off. In one embodiment,sensor 130 may sense a condition of a patient indicating whether the patient is asleep such as whether the eyes are closed, the breathing patterns, or the heart rate. Advantageously,device 10 shuts on or off in response to any number of physical, biological and/or chemical rhythms of the body indicative of whether the patient is sleeping. For example, the system may sense whether the patient's eyes shut for an extended period of time signifying that the patient is napping, sleeping or resting. Alternatively, the system may monitor activity or motion, heart rate, or respiration. Other chemical characteristics may also be monitored to determine whether the treatment therapy should be stopped such as oxygen partial pressure, carbon dioxide concentration, or glucose and insulin concentrations. These characteristics may be measured, for example, in the blood stream or other bodily fluid. Any type of sensor may be used to sense the above characteristics of the body. More detailed description ofsensor 130 and other examples of sensors are disclosed in U.S. Pat. No. 5,716,377 entitled “Method of Treating Movement Disorders By Brain Infusion,” issued on Feb. 10, 1998 and assigned to Medtronic, Inc., which is incorporated herein by reference in its entirety. Other such sensors are also disclosed in U.S. Pat. Nos. 5,683,422; 5,702,429; 5,713,923; 5,716,316; 5,792,186; 5,814,014; and 5,824,021, all of which are incorporated herein by reference in their entireties. -
Signal generator 10 may be automatically turned on or off if any of the conditions sensed bysensor 130 indicates that the patient is sleeping.Sensor 130 may be used in conjunction with or as an alternative to timer 201 (or a real time clock). If used in conjunction withtimer 201,signal generator 10 may operate with a default of being “off” at night and a default of being “on” during the day. The default is determined bytimer 201. During the day,device 10 may shut off only when a certain threshold of characteristics are sensed bysensor 130 such that it is clear that the patient is asleep. At night when the patient is normally asleep,device 10 may be turned on only whensensor 130 senses characteristics that clearly indicate that the patient has awaken.Sensor 130 provides information to signalgenerator 10 to determine whether to deviate from the default. These threshold parameters may be adjusted by the physician or the patient. The patient may also have the capability to manually turn on or offsignal generator 10 as provided in the art. -
Sensor 130 may also be used to provide closed-loop feedback control of the treatment therapy during periods whendevice 10 is in operation. Alternatively, one or more additional sensors may be implemented for feedback control. The additional sensor is attached to or implanted into a portion of a patient's body suitable for detecting symptoms of a disorder being treated, such as a movement disorder or ischemic pain. The additional sensor is adapted to sense an attribute of the symptom to be controlled or an important related symptom. For motion disorders that result in abnormal movement of an arm, such asarm 122, sensor may be a motion detector implanted inarm 122 as shown inFIG. 4 . Such feedback control techniques are disclosed in the patents described above. - Referring to
FIG. 4 , the output ofsensor 130 is coupled bycable 132 to signalgenerator 10. Alternatively, the output of an external sensor would communicate withsignal generator 10 via telemetry. In the embodiment ofFIG. 4 ,sensor 130 monitors heart rate and optionally movement. -
FIG. 5 illustrates a schematic block diagram of thesignal generator 10 ofFIG. 2 including a sensor signal input fromsensor 130.Sensor 130 is coupled to an analog todigital converter 206 ofsignal generator 10. The output of the analog todigital converter 206 is connected to amicroprocessor 200 through aperipheral bus 202 including address, data and control lines. Depending upon the particular sensor signal used, an analog to digital converter would not be necessary. The output fromsensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal forsignal generator 10. -
Microprocessor 200 is coupled totimer 201 to receive timing information and tosensor 130 to receive patient information.Microprocessor 200 may then responsively determine whether the treatment therapy should be turned on or off. Other componentry ofsignal generator 10 is shown to generate the desired signal pulsing parameters and/or to provide feedback control of the treatment therapy. The present invention may be practiced withoutmicroprocessor 200. For example, a controller or electrical circuitry having the desired functionality may be implemented in place ofmicroprocessor 200 to receive the timer and/or sensor information and process the information to determine whether treatment therapy is to be delivered. - The present invention is equally suitable for use in drug infusion systems to automatically provide or cease providing drug therapy to a patient. As shown in
FIG. 6 , the drug infusion system includes apump 410 having at least one reservoir for storing at least one drug. The drug may be delivered via acatheter 422.Catheter 422 may be coupled to a single tube 422A or tube 422A may be divided into twin tubes, tube 422A and a second tube (not shown), that are implanted into the brain bilaterally. The second tube may supply drugs from a second catheter and pump or may supply drugs fromcatheter 422 to a second location within the brain B. Such drug infusion systems that may incorporate the present invention are disclosed in U.S. Pat. Nos. 5,711,316; 5,713,923; 5,735,814; and 5,782,798, each of which are incorporated herein by reference in their entireties. The drug pump may include similar componentry as that of thesignal generators 10 discussed inFIGS. 2, 3 and 5. - Advantageously, the present invention may be utilized in a number of different treatment therapies, including, but not limited to, treatment of pain, movement disorders and other neurological disorders such as epilepsy, to provide a mechanism to automatically turn off treatment therapy during periods that it is not required or necessary. As used herein, the term disorder includes any disorder, illness or maladies. Additionally, the present invention may automatically turn on the treatment therapy during or right before the patient requires the treatment therapy.
- Those skilled in that art will recognize that the preferred embodiments may be altered or amended without departing from the true spirit and scope of the invention, as defined in the accompanying claims.
Claims (8)
1. A drug delivery system for treatment of a disorder comprising in combination:
(a) an implantable pump having at least one reservoir for storing at least one drug;
(b) a real time clock coupled to the pump and providing time-of-day information; and
(c) at least one implantable catheter coupled to the pump and adapted to deliver the drug to at least one predetermined site in a body of a patient, wherein the pump is configured to adapt delivery of the drug in response to the time-of-day information provided by the real time clock and the pump is further configured to adapt delivery of the drug in response to a change in rhythms of the patient.
2. A drug delivery system for treatment of a disorder comprising in combination:
an implantable pump having a reservoir for storing a drug;
a implantable microprocessor for controlling the pump;
a real time clock coupled to the microprocessor and providing time-of-day information; and
an implantable catheter couple to the pump, the catheter configured to deliver the drug to a predetermined site in a body of the patient at a controlled delivery rate, wherein the microprocessor varies the delivery rate of the drug in response to the time-of-day information provided by the real time clock.
3. The drug delivery system of claim 2 , wherein the microprocessor causes the pump to provide a first delivery rate in response to a first time-of-day information from the real time clock and the microprocessor causes the pump to provide a second delivery rate in response to a second time-of-day information from the real time clock.
4. The drug delivery system of claim 3 , further comprising a sensor configured to provide feedback regarding a patient characteristic, wherein the microprocessor modifies the drug delivery in response to both the feedback provided by the sensor and the time-of-day information provided by the real time clock.
5. The drug delivery system of claim 3 , wherein the second delivery rate is zero.
6. A method of delivering a drug to a patient from an implanted pump, comprising:
determining a time-of-day;
determining an appropriate delivery rate of the drug based on the time-of-day; and
providing the drug to the patient via an implanted catheter at the appropriate rate.
7. The method of claim 6 , further comprising the step of providing a feedback signal based on a patient characteristic, wherein the step of determining the appropriate delivery rate includes consideration of the feedback signal.
8. The method of claim 6 , further comprising the step of modifying the delivery rate in response to a change in the time-of-day information.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/093,747 US20050234432A1 (en) | 1999-04-30 | 2005-03-30 | Therapeutic treatment of disorders based on timing information |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30314499A | 1999-04-30 | 1999-04-30 | |
US10/000,638 US6923784B2 (en) | 1999-04-30 | 2001-10-31 | Therapeutic treatment of disorders based on timing information |
US11/093,747 US20050234432A1 (en) | 1999-04-30 | 2005-03-30 | Therapeutic treatment of disorders based on timing information |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/000,638 Continuation US6923784B2 (en) | 1999-04-30 | 2001-10-31 | Therapeutic treatment of disorders based on timing information |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050234432A1 true US20050234432A1 (en) | 2005-10-20 |
Family
ID=46278423
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/000,638 Expired - Fee Related US6923784B2 (en) | 1999-04-30 | 2001-10-31 | Therapeutic treatment of disorders based on timing information |
US11/093,747 Abandoned US20050234432A1 (en) | 1999-04-30 | 2005-03-30 | Therapeutic treatment of disorders based on timing information |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/000,638 Expired - Fee Related US6923784B2 (en) | 1999-04-30 | 2001-10-31 | Therapeutic treatment of disorders based on timing information |
Country Status (1)
Country | Link |
---|---|
US (2) | US6923784B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021216350A1 (en) * | 2020-04-20 | 2021-10-28 | Ivenix, Inc. | Fluid pump notification and control based on monitored feedback |
Families Citing this family (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US9113801B2 (en) | 1998-08-05 | 2015-08-25 | Cyberonics, Inc. | Methods and systems for continuous EEG monitoring |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
JP2000311992A (en) * | 1999-04-26 | 2000-11-07 | Toshiba Corp | Nonvolatile semiconductor memory device and manufacture thereof |
US6923784B2 (en) * | 1999-04-30 | 2005-08-02 | Medtronic, Inc. | Therapeutic treatment of disorders based on timing information |
CA2381951A1 (en) | 1999-08-18 | 2001-02-22 | Microchips, Inc. | Thermally-activated microchip chemical delivery devices |
US7130692B2 (en) * | 2000-02-23 | 2006-10-31 | The Trustees Of The University Of Pennsylvania | Portable electrotherapy device for treating osteoarthritis and other diseases, defects and injuries of the knee joint |
US7465566B2 (en) | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US8313908B2 (en) | 2000-02-23 | 2012-11-20 | The Trustees Of The University Of Pennsylvania | Regulation of stem cell gene production with specific and selective electric and electromagnetic fields |
US7981611B2 (en) | 2000-02-23 | 2011-07-19 | The Trustees Of The University Of Pennsylvania | Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields |
ES2420279T3 (en) * | 2000-03-02 | 2013-08-23 | Microchips, Inc. | Microfabricated devices and methods for storage and selective exposure of chemicals |
WO2002030264A2 (en) | 2000-10-10 | 2002-04-18 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
CA2432438C (en) | 2001-01-09 | 2011-04-26 | Microchips, Inc. | Flexible microchip devices for ophthalmic and other applications |
AU2002326304A1 (en) * | 2001-05-31 | 2002-12-16 | Massachusetts Institute Of Technology | Microchip devices with improved reservoir opening |
IL145700A0 (en) * | 2001-09-30 | 2002-06-30 | Younis Imad | Electrode system for neural applications |
US7110820B2 (en) * | 2002-02-05 | 2006-09-19 | Tcheng Thomas K | Responsive electrical stimulation for movement disorders |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US20070135875A1 (en) * | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
AU2003303288B2 (en) | 2002-08-16 | 2006-12-07 | Microchips, Inc. | Controlled release device and method |
AU2003284018A1 (en) * | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for neural stimulation and controlled drug delivery |
AU2003279842A1 (en) * | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
AU2003285889A1 (en) | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Control of treatment therapy during start-up and during operation of a medical device system |
EP1583464B1 (en) * | 2002-10-15 | 2014-04-09 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
AU2003287159A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Synchronization and calibration of clocks for a medical device and calibrated clock |
US20040138647A1 (en) * | 2002-10-15 | 2004-07-15 | Medtronic, Inc. | Cycle mode providing redundant back-up to ensure termination of treatment therapy in a medical device system |
WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
AU2003286451A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Signal quality monitoring and control for a medical device system |
US8543214B2 (en) * | 2002-10-15 | 2013-09-24 | Medtronic, Inc. | Configuring and testing treatment therapy parameters for a medical device system |
ATE449561T1 (en) | 2002-10-15 | 2009-12-15 | Medtronic Inc | PHASE SHIFT OF NEUROLOGICAL SIGNALS IN A MEDICAL DEVICE SYSTEM |
EP1558130A4 (en) | 2002-10-15 | 2009-01-28 | Medtronic Inc | Screening techniques for management of a nervous system disorder |
EP1629341A4 (en) | 2002-10-15 | 2008-10-15 | Medtronic Inc | Multi-modal operation of a medical device system |
US7933646B2 (en) * | 2002-10-15 | 2011-04-26 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
US7035690B2 (en) | 2002-11-15 | 2006-04-25 | Medtronic, Inc. | Human-implantable-neurostimulator user interface having multiple levels of abstraction |
AU2003303386A1 (en) * | 2002-12-23 | 2004-07-22 | Medtronic, Inc. | Permeable membrane catheters, systems, and methods |
US7266412B2 (en) * | 2003-04-22 | 2007-09-04 | Medtronic, Inc. | Generation of multiple neurostimulation therapy programs |
US8396565B2 (en) | 2003-09-15 | 2013-03-12 | Medtronic, Inc. | Automatic therapy adjustments |
EP1694200B1 (en) | 2003-11-03 | 2010-09-29 | MicroCHIPS, Inc. | Medical device for sensing glucose |
US7317941B2 (en) * | 2003-11-13 | 2008-01-08 | Medtronic, Inc. | Time syncrhonization of data |
IL159401A0 (en) * | 2003-12-16 | 2004-06-01 | Michael Gordon | A method and device for controlled release of chemicals and biological substances by photochemical reactions |
CA2553199C (en) * | 2004-01-12 | 2014-03-25 | The Trustees Of The University Of Pennsylvania | System for up-regulating bone morphogenetic protein (bmp) gene expression in bone cells via the application of fields generated by specific electric and electromagnetic signals |
WO2005077450A2 (en) * | 2004-02-10 | 2005-08-25 | Synecor, Llc | Intravascular delivery system for therapeutic agents |
CN100488635C (en) * | 2004-09-01 | 2009-05-20 | 微芯片公司 | Multi-cap reservoir devices for controlled release or exposure of reservoir contents |
US7937143B2 (en) * | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US20070083239A1 (en) * | 2005-09-23 | 2007-04-12 | Denise Demarais | Methods and apparatus for inducing, monitoring and controlling renal neuromodulation |
US8788044B2 (en) | 2005-01-21 | 2014-07-22 | Michael Sasha John | Systems and methods for tissue stimulation in medical treatment |
US20080288023A1 (en) * | 2005-08-31 | 2008-11-20 | Michael Sasha John | Medical treatment using patient states, patient alerts, and hierarchical algorithms |
US9089713B2 (en) * | 2005-08-31 | 2015-07-28 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
US8965509B2 (en) | 2005-08-31 | 2015-02-24 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
US7957809B2 (en) * | 2005-12-02 | 2011-06-07 | Medtronic, Inc. | Closed-loop therapy adjustment |
EP1960046A1 (en) * | 2005-12-02 | 2008-08-27 | Medtronic, Inc. | Closed-loop therapy adjustment |
US7853322B2 (en) * | 2005-12-02 | 2010-12-14 | Medtronic, Inc. | Closed-loop therapy adjustment |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US7822483B2 (en) * | 2006-02-24 | 2010-10-26 | Medtronic, Inc. | Electrical and activation field models for configuring stimulation therapy |
US8612024B2 (en) | 2006-02-24 | 2013-12-17 | Medtronic, Inc. | User interface with 3D environment for configuring stimulation therapy |
US7657319B2 (en) * | 2006-02-24 | 2010-02-02 | Medtronic, Inc. | Programming interface with an unwrapped 2D view of a stimulation lead with complex electrode array geometry |
US7848802B2 (en) | 2006-02-24 | 2010-12-07 | Medtronic, Inc. | Programming interface with a concentric axial view of a stimulation lead with complex electrode array geometry |
US7826902B2 (en) | 2006-02-24 | 2010-11-02 | Medtronic, Inc. | User interface with 2D views for configuring stimulation therapy |
US8543217B2 (en) | 2006-02-24 | 2013-09-24 | Medtronic, Inc. | Stimulation templates for configuring stimulation therapy |
US7676273B2 (en) | 2006-02-24 | 2010-03-09 | Medtronic, Inc. | Stimulation templates for programming a stimulation lead with complex electrode array geometry |
US8380321B2 (en) | 2006-02-24 | 2013-02-19 | Medtronic, Inc. | Programming interface with a cross-sectional view of a stimulation lead with complex electrode array geometry |
US8452415B2 (en) | 2006-02-24 | 2013-05-28 | Medtronic, Inc. | Electrical and activation field models for programming a stimulation lead with complex electrode array geometry |
US20080027515A1 (en) | 2006-06-23 | 2008-01-31 | Neuro Vista Corporation A Delaware Corporation | Minimally Invasive Monitoring Systems |
JP5241714B2 (en) | 2006-07-07 | 2013-07-17 | プロテウス デジタル ヘルス, インコーポレイテッド | Smart parenteral delivery system |
EP2079504B8 (en) * | 2006-11-06 | 2023-04-26 | Fisher & Paykel Healthcare Limited | Integrated humidifier chamber & lid |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
US20080183097A1 (en) | 2007-01-25 | 2008-07-31 | Leyde Kent W | Methods and Systems for Measuring a Subject's Susceptibility to a Seizure |
EP2126785A2 (en) | 2007-01-25 | 2009-12-02 | NeuroVista Corporation | Systems and methods for identifying a contra-ictal condition in a subject |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
CN104069567A (en) | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | Drug delivery device |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
WO2008117214A1 (en) * | 2007-03-27 | 2008-10-02 | Koninklijke Philips Electronics N.V. | Automatic drug administration with reduced power consumption |
US8781595B2 (en) | 2007-04-30 | 2014-07-15 | Medtronic, Inc. | Chopper mixer telemetry circuit |
US8224443B2 (en) * | 2007-05-08 | 2012-07-17 | Cardiac Pacemakers, Inc. | Method for controlling pacemaker therapy |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US20090069862A1 (en) * | 2007-09-11 | 2009-03-12 | Brian Michael Shelton | Adaptive Telemetry Wakeup for an Implantable Medical Device |
US10561845B2 (en) * | 2007-09-24 | 2020-02-18 | Medtronic, Inc. | Therapy adjustment based on patient event indication |
US8380314B2 (en) | 2007-09-26 | 2013-02-19 | Medtronic, Inc. | Patient directed therapy control |
WO2009042172A2 (en) * | 2007-09-26 | 2009-04-02 | Medtronic, Inc. | Frequency selective monitoring of physiological signals |
US20090088732A1 (en) * | 2007-10-02 | 2009-04-02 | Daniel Hernandez Villegas | Rapid Refill Programming for Implantable Drug Pump |
US9129047B2 (en) | 2007-10-03 | 2015-09-08 | Medallion Therapeutics, Inc. | Programming and bolus monitoring device for an implantable drug pump |
US8121694B2 (en) * | 2007-10-16 | 2012-02-21 | Medtronic, Inc. | Therapy control based on a patient movement state |
WO2009055733A1 (en) | 2007-10-25 | 2009-04-30 | Proteus Biomedical, Inc. | Fluid transfer port information system |
US20090204173A1 (en) | 2007-11-05 | 2009-08-13 | Zi-Ping Fang | Multi-Frequency Neural Treatments and Associated Systems and Methods |
WO2009067463A1 (en) | 2007-11-19 | 2009-05-28 | Proteus Biomedical, Inc. | Body-associated fluid transport structure evaluation devices |
US20090149799A1 (en) * | 2007-12-05 | 2009-06-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for chemical modulation of neural activity |
US8180447B2 (en) | 2007-12-05 | 2012-05-15 | The Invention Science Fund I, Llc | Method for reversible chemical modulation of neural activity |
EP2231229A1 (en) | 2007-12-18 | 2010-09-29 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US20090171168A1 (en) | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
CN101925377A (en) | 2008-01-25 | 2010-12-22 | 麦德托尼克公司 | The detection of Sleep stages |
US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
US9440084B2 (en) * | 2008-07-11 | 2016-09-13 | Medtronic, Inc. | Programming posture responsive therapy |
US8219206B2 (en) * | 2008-07-11 | 2012-07-10 | Medtronic, Inc. | Dwell time adjustments for posture state-responsive therapy |
US8209028B2 (en) | 2008-07-11 | 2012-06-26 | Medtronic, Inc. | Objectification of posture state-responsive therapy based on patient therapy adjustments |
US8886302B2 (en) | 2008-07-11 | 2014-11-11 | Medtronic, Inc. | Adjustment of posture-responsive therapy |
US9050471B2 (en) | 2008-07-11 | 2015-06-09 | Medtronic, Inc. | Posture state display on medical device user interface |
US8708934B2 (en) * | 2008-07-11 | 2014-04-29 | Medtronic, Inc. | Reorientation of patient posture states for posture-responsive therapy |
US8249718B2 (en) * | 2008-07-11 | 2012-08-21 | Medtronic, Inc. | Programming posture state-responsive therapy with nominal therapy parameters |
US9592387B2 (en) * | 2008-07-11 | 2017-03-14 | Medtronic, Inc. | Patient-defined posture states for posture responsive therapy |
US8504150B2 (en) | 2008-07-11 | 2013-08-06 | Medtronic, Inc. | Associating therapy adjustments with posture states using a stability timer |
US8280517B2 (en) | 2008-09-19 | 2012-10-02 | Medtronic, Inc. | Automatic validation techniques for validating operation of medical devices |
US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US9327121B2 (en) | 2011-09-08 | 2016-05-03 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
MX2011004817A (en) | 2008-11-07 | 2011-07-28 | Insuline Medical Ltd | Device and method for drug delivery. |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8635694B2 (en) * | 2009-01-10 | 2014-01-21 | Kaspersky Lab Zao | Systems and methods for malware classification |
ES2624748T3 (en) | 2009-04-22 | 2017-07-17 | Nevro Corporation | Selective high frequency modulation of the spinal cord for pain inhibition with reduced side effects, and associated systems and methods |
EP2756864B1 (en) | 2009-04-22 | 2023-03-15 | Nevro Corporation | Spinal cord modulation systems for inducing paresthetic and anesthetic effects |
US9327070B2 (en) * | 2009-04-30 | 2016-05-03 | Medtronic, Inc. | Medical device therapy based on posture and timing |
US8175720B2 (en) | 2009-04-30 | 2012-05-08 | Medtronic, Inc. | Posture-responsive therapy control based on patient input |
US9026223B2 (en) | 2009-04-30 | 2015-05-05 | Medtronic, Inc. | Therapy system including multiple posture sensors |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
US8498710B2 (en) | 2009-07-28 | 2013-07-30 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
DK2306352T3 (en) * | 2009-09-25 | 2013-04-08 | Hoffmann La Roche | Diabetic therapy apparatus, which allows for the shifting of parameter profiles |
US9770204B2 (en) | 2009-11-11 | 2017-09-26 | Medtronic, Inc. | Deep brain stimulation for sleep and movement disorders |
US8388555B2 (en) | 2010-01-08 | 2013-03-05 | Medtronic, Inc. | Posture state classification for a medical device |
US8579834B2 (en) * | 2010-01-08 | 2013-11-12 | Medtronic, Inc. | Display of detected patient posture state |
US9956418B2 (en) | 2010-01-08 | 2018-05-01 | Medtronic, Inc. | Graphical manipulation of posture zones for posture-responsive therapy |
US9357949B2 (en) | 2010-01-08 | 2016-06-07 | Medtronic, Inc. | User interface that displays medical therapy and posture data |
US9014779B2 (en) | 2010-02-01 | 2015-04-21 | Proteus Digital Health, Inc. | Data gathering system |
EP2531096A4 (en) | 2010-02-01 | 2013-09-11 | Proteus Digital Health Inc | Two-wrist data gathering system |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
US9566441B2 (en) | 2010-04-30 | 2017-02-14 | Medtronic, Inc. | Detecting posture sensor signal shift or drift in medical devices |
US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
CN107007348B (en) | 2010-10-25 | 2019-05-31 | 美敦力Af卢森堡有限责任公司 | For the estimation of nerve modulation treatment and device, the system and method for feedback |
AU2011336606B2 (en) | 2010-11-30 | 2016-06-23 | Nevro Corporation | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
US9498162B2 (en) | 2011-04-25 | 2016-11-22 | Cyberonics, Inc. | Identifying seizures using heart data from two or more windows |
US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
US9549677B2 (en) | 2011-10-14 | 2017-01-24 | Flint Hills Scientific, L.L.C. | Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm |
AU2013230781B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
RU2644933C2 (en) | 2012-03-08 | 2018-02-14 | Медтроник Аф Люксембург Сарл | Biomarker samples selection as part of devices for neuromodulation and relevant systems and methods |
US9907959B2 (en) | 2012-04-12 | 2018-03-06 | Medtronic, Inc. | Velocity detection for posture-responsive therapy |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
US9681836B2 (en) | 2012-04-23 | 2017-06-20 | Cyberonics, Inc. | Methods, systems and apparatuses for detecting seizure and non-seizure states |
US9737719B2 (en) | 2012-04-26 | 2017-08-22 | Medtronic, Inc. | Adjustment of therapy based on acceleration |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9924904B2 (en) | 2014-09-02 | 2018-03-27 | Medtronic, Inc. | Power-efficient chopper amplifier |
US11167139B2 (en) | 2015-03-20 | 2021-11-09 | Medtronic Sg, Llc | Method and apparatus for multi modal electrical modulation of pain using composite electromagnetic fields |
CA2983582A1 (en) | 2015-03-20 | 2016-09-29 | Ricardo Vallejo | Method and apparatus for multimodal electrical modulation of pain |
US10850102B2 (en) | 2015-03-20 | 2020-12-01 | Medtronic Sg, Llc | Method and apparatus for multimodal electrical modulation of pain |
WO2017040472A1 (en) * | 2015-09-01 | 2017-03-09 | Med-El Elektromedizinische Geraete Gmbh | Patient specific frequency modulation adaption |
US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
AU2017211121B2 (en) | 2016-01-25 | 2022-02-24 | Nevro Corp. | Treatment of congestive heart failure with electrical stimulation, and associated systems and methods |
US10799701B2 (en) | 2016-03-30 | 2020-10-13 | Nevro Corp. | Systems and methods for identifying and treating patients with high-frequency electrical signals |
US11446504B1 (en) | 2016-05-27 | 2022-09-20 | Nevro Corp. | High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods |
AU2020207940A1 (en) | 2019-01-17 | 2021-08-12 | Nevro Corp. | Sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection, and associated systems and methods |
US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
US11918811B2 (en) | 2019-05-06 | 2024-03-05 | Medtronic Sg, Llc | Method and apparatus for multi modal or multiplexed electrical modulation of pain using composite electromagnetic fields |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US4570640A (en) * | 1981-08-06 | 1986-02-18 | Barsa John E | Sensory monitoring apparatus and method |
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US5113869A (en) * | 1990-08-21 | 1992-05-19 | Telectronics Pacing Systems, Inc. | Implantable ambulatory electrocardiogram monitor |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5683422A (en) * | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5702426A (en) * | 1994-11-16 | 1997-12-30 | Ela Medical S.A. | Automatic adjustment of electrical signal parameters |
US5702429A (en) * | 1996-04-04 | 1997-12-30 | Medtronic, Inc. | Neural stimulation techniques with feedback |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US5716377A (en) * | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5716318A (en) * | 1995-04-14 | 1998-02-10 | The University Of North Carolina At Chapel Hill | Method of treating cardiac arrest and apparatus for same |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5782798A (en) * | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5824021A (en) * | 1996-04-25 | 1998-10-20 | Medtronic Inc. | Method and apparatus for providing feedback to spinal cord stimulation for angina |
US5928272A (en) * | 1998-05-02 | 1999-07-27 | Cyberonics, Inc. | Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity |
US6066163A (en) * | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US6475180B2 (en) * | 1992-09-09 | 2002-11-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US6923784B2 (en) * | 1999-04-30 | 2005-08-02 | Medtronic, Inc. | Therapeutic treatment of disorders based on timing information |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2734181B1 (en) * | 1995-05-18 | 1997-06-13 | Commissariat Energie Atomique | TREATMENT OF FLY ASH FROM A WASTE INCINERATOR CONTAINING TOXIC METAL CHLORIDES |
-
2001
- 2001-10-31 US US10/000,638 patent/US6923784B2/en not_active Expired - Fee Related
-
2005
- 2005-03-30 US US11/093,747 patent/US20050234432A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US4570640A (en) * | 1981-08-06 | 1986-02-18 | Barsa John E | Sensory monitoring apparatus and method |
US5113869A (en) * | 1990-08-21 | 1992-05-19 | Telectronics Pacing Systems, Inc. | Implantable ambulatory electrocardiogram monitor |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US6475180B2 (en) * | 1992-09-09 | 2002-11-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US5702426A (en) * | 1994-11-16 | 1997-12-30 | Ela Medical S.A. | Automatic adjustment of electrical signal parameters |
US5716318A (en) * | 1995-04-14 | 1998-02-10 | The University Of North Carolina At Chapel Hill | Method of treating cardiac arrest and apparatus for same |
US6066163A (en) * | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US5702429A (en) * | 1996-04-04 | 1997-12-30 | Medtronic, Inc. | Neural stimulation techniques with feedback |
US5792186A (en) * | 1996-04-25 | 1998-08-11 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5716377A (en) * | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5824021A (en) * | 1996-04-25 | 1998-10-20 | Medtronic Inc. | Method and apparatus for providing feedback to spinal cord stimulation for angina |
US5683422A (en) * | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5814014A (en) * | 1996-04-30 | 1998-09-29 | Medtronic Incorporated | Techniques of treating neurodegenerative disorders by brain infusion |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US5782798A (en) * | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5928272A (en) * | 1998-05-02 | 1999-07-27 | Cyberonics, Inc. | Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity |
US6923784B2 (en) * | 1999-04-30 | 2005-08-02 | Medtronic, Inc. | Therapeutic treatment of disorders based on timing information |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021216350A1 (en) * | 2020-04-20 | 2021-10-28 | Ivenix, Inc. | Fluid pump notification and control based on monitored feedback |
Also Published As
Publication number | Publication date |
---|---|
US20020038137A1 (en) | 2002-03-28 |
US6923784B2 (en) | 2005-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6923784B2 (en) | Therapeutic treatment of disorders based on timing information | |
US7366572B2 (en) | Controlling therapy based on sleep quality | |
US9623248B2 (en) | Collecting sleep quality information via a medical device | |
US5335657A (en) | Therapeutic treatment of sleep disorder by nerve stimulation | |
US8805493B2 (en) | Monitoring of chronobiological rhythms for disease and drug management using one or more implantable device | |
JP3493197B2 (en) | Treatment of migraine by nerve stimulation | |
US8731656B2 (en) | Closed-loop therapy adjustment | |
US10471264B2 (en) | Closed-loop therapy adjustment | |
US7769464B2 (en) | Therapy adjustment | |
US8126567B2 (en) | Therapy adjustment | |
US20020091308A1 (en) | Method and apparatus for the synchronized therapeutic treatment of a life form | |
US20110112590A1 (en) | Deep brain stimulation for sleep and movement disorders | |
US20120010680A1 (en) | Conditional electrical stimulation | |
EP1960047A1 (en) | Closed-loop therapy adjustment | |
WO2008117226A1 (en) | Drug administration based on a patient's activity status measured by acceleration sensors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |